Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of Cytotect prophylaxis and pre-transplant Vdelta2-negative CD16-positive gamma-delta T cells for CMV prevention after kidney transplantation
2020-005582-13Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Dec 2020
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of human cytomegalovirus immune globulin in cytomegalovirus disease (CMV), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Association between pre-transplant LTgd CD16+ level and CMV infection. Started Dec 2020; status: completed.
02
Drugs
human cytomegalovirus immune globulin
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2020-005582-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005582-13.